Chong Kun Dang announces domestic exclusive sales agreement of lupus treatment

Published: 2015-12-16 15:18:56

Updated: 2015-12-16 15:18:56

On the 14^th, Chong Kun Dang(CEO Young-joo Kim) announced the domestic exclusive sales agreement of ‘IFN-K(interferenon-α-kinoid), a systemic lupus erythematosus(hereinafter referring to lupus), with French Neoxacs.

IFN-K is a treatment vaccine whose phase 2 clinical trials are being process by Neoxacs in Europe, such as France and Germany.

When the clinical trial is completed, Chong Kun Dan w...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.